Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To estimate the cost-effectiveness of noncardia gastric adenocarcinoma (NCGA) screening strategies based on new biomarker and endoscopic technologies. DESIGN: Using an intestinal-type NCGA microsimulation model, we evaluated the following one-time screening strategies for US men: (1) serum pepsinogen to detect gastric atrophy (with endoscopic follow-up of positive screen results), (2) endoscopic screening to detect dysplasia and asymptomatic cancer (with endoscopic mucosal resection (EMR) treatment for detected lesions) and (3) Helicobacter pylori screening and treatment. Screening performance, treatment effectiveness, cancer and cost data were based on published literature and databases. Subgroups included current, former and never smokers. Outcomes included lifetime cancer risk and incremental cost-effectiveness ratios (ICERs), expressed as cost per quality-adjusted-life-year (QALY) gained. RESULTS: Screening the general population at age 50 years reduced the lifetime intestinal-type NCGA risk (0.24%) by 26.4% with serum pepsinogen screening, 21.2% with endoscopy and EMR and 0.2% with H. pylori screening/treatment. Targeting current smokers reduced the lifetime risk (0.35%) by 30.8%, 25.5%, and 0.1%, respectively. For all subgroups, serum pepsinogen screening was more effective and more cost-effective than all other strategies, although its ICER varied from $76,000/QALY (current smokers) to $105,400/QALY (general population). Results were sensitive to H. pylori prevalence, screen age and serum pepsinogen test sensitivity. Probabilistic sensitivity analysis found that at a $100,000/QALY willingness-to-pay threshold, the probability that serum pepsinogen screening was preferred was 0.97 for current smokers. CONCLUSIONS: Although not warranted for the general population, targeting high-risk smokers for serum pepsinogen screening may be a cost-effective strategy to reduce intestinal-type NCGA mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Use and misuse of population attributable fractions
Rockhill, B., Newman, B., & Weinberg, C. (1998) · American Journal of Public Health · doi:10.2105/ajph.88.1.15 · Cited by 1,683
Cost-Effectiveness in Health and Medicine
(2016) · doi:10.1093/acprof:oso/9780190492939.001.0001 · Cited by 1,552
50-Year Trends in Smoking-Related Mortality in the United States
Thun, M. J., Carter, B. D., Feskanich, D., Freedman, N. D., Prentice, R., Lopez, A. D., Hartge, P., & Gapstur, S. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1211127 · Cited by 1,177
A model for gastric cancer epidemiology
CORREA, P. (1975) · The Lancet · doi:10.1016/s0140-6736(75)90498-5 · Cited by 1,158
Relationships Among Serum Pepsinogen I, Serum Pepsinogen II, and Gastric Mucosal Histology
Samloff, I. M., Varis, K., Ihamaki, T., Siurala, M., & Rotter, J. I. (1982) · Gastroenterology · doi:10.1016/0016-5085(82)90176-7 · Cited by 414
Pathology of gastric intestinal metaplasia: clinical implications
Correa, P., Piazuelo, B. M., & Wilson, K. T. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.728 · Cited by 405
Gold, M. R., Franks, P., McCoy, K. I., & Fryback, D. G. (1998) · Medical Care · doi:10.1097/00005650-199806000-00002 · Cited by 357
Cited by
Pimentel-Nunes, P., Libânio, D., Marcos-Pinto, R., Areia, M., Leja, M., Esposito, G., Garrido, M., Kikuste, I., Megraud, F., Matysiak-Budnik, T., et al. (2019) · Endoscopy · doi:10.1055/a-0859-1883 · Cited by 993
Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention
Thrift, A. P., Wenker, T. N., & El-Serag, H. B. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00747-0 · Cited by 828
Banks, M., Graham, D., Jansen, M., Gotoda, T., Coda, S., di Pietro, M., Uedo, N., Bhandari, P., Pritchard, D. M., Kuipers, E. J., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-318126 · Cited by 647
Ajani, J. A., Lee, J., Sano, T., Janjigian, Y. Y., Fan, D., & Song, S. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.36 · Cited by 594
Metadata
- Authors
- Yeh, J. M., Hur, C., Ward, Z., Schrag, D., & Goldie, S. J.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2015-03-16
- Volume
- 65
- Issue
- 4
- Pages
- 563-574
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W1989737381
- Cited by
- 105
- References
- 9
- FWCI
- 9.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis. https://app.cochat.ai/papers/10.1136/gutjnl-2014-308588
- The paper
- Yeh, J. M., Hur, C., Ward, Z., Schrag, D., & Goldie, S. J. (2016). Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis. Gut. https://doi.org/10.1136/gutjnl-2014-308588
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.